HUTCHMED (China) Limited
HCM.L · LSE
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -3.70 |
| FCF Yield | -1.51% | -1.57% | 0.46% | 0.35% |
| EV / EBITDA | 1,118.29 | 2,006.05 | -681.68 | -919.05 |
| Quality | ||||
| ROIC | -0.11% | -0.11% | -0.64% | -0.64% |
| Gross Margin | 39.65% | 39.65% | -17.36% | -17.36% |
| Cash Conversion Ratio | -0.16 | -0.16 | 3.38 | 3.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.35% | 1.35% | 13.91% | 14.48% |
| Free Cash Flow Growth | 0.00% | -352.77% | 0.00% | 165.09% |
| Safety | ||||
| Net Debt / EBITDA | -976.25 | -7.67 | 12.71 | 12.71 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1.73 | 3.78 | 3.78 |
| Cash Conversion Cycle | 48.30 | 100.35 | 96.76 | 89.99 |